- Email: [email protected]
MRI
132
A B S T R A C T S / E U R O P E A N U R O L O G Y S U P P L E M E N T S 13 (2014) 103—194
with cancer, but which were not specific for urological cancer, were not included in this study. Each of the selected apps was reviewed by three graders to unanimously determine their price, type of developer (individual or company), target audience (health care professional or general population) and type of cancer. Results: We found 139 iOS applications designed for urology, of which 19% were cancer specific, and 128 Android urological applications, 12% of which were cancer specific. All variables were compared between Android and iOS apps using Chi-square goodness-offit test for the numbers of apps and Fisher exact testing (for nominal variables). There was no statistically significant difference between the number of urological cancer apps in both stores (p=0.086). Moreover, Fisher test shows that there was no statistically significant differences between Android and iOS in app price (paid or free, p=0.129), type of developer (p=0.566) and target audience (p=0.507). From a total of 34 urological cancer specific apps, 21% were available in both stores, 56% were exclusively on Apple’s App Store and 24% on Google’s Play Store. The majority were free (56%), developed by companies (65%) and designed for the general population (59%). Most were prostate cancer specific (74%); 9% were for general urological cancers, 9% for testicular, 6% for bladder and 3% for renal cell cancer. There were no apps specific for upper urinary tract, urethral or penile cancer. Conclusions: To our knowledge, this is the first study that completely reviews and compares mobile apps designed for urological cancer. There are some apps available exclusively in a specific platform, which could represent the difference in review policy (all iOS apps have to be approved by Apple; Android apps are mostly unregulated). We can conclude that urological cancer specific apps represent less than a quarter of all urology related apps, with no statistically significant differences between the two most popular mobile platforms. In addition, the total number of available urological cancer specific apps is much lower than that of breast cancer (total = 238, Android = 138, iOS = 100). With the foreseeable growth of the mHealth app market, expected to reach a value of more than USD 26bn in 2017, we look forward to an increase in the quantity and quality of available medical apps. P062 Full functional length urethral sphincter preservation during open radical prostatectomy – will it improve the continence rate? R.K. Shimpi. Uro-Andrology Clinic, Dept. of Urology, Pune, India Introduction & Objectives: The full length of the urethral sphincter is the key for urinary continence after Radical Prostatectomy. As demonstrated by various studies, the Intra-Prostatic Urethra between the apex and verumontanum is an important part of the urethral sphincter complex. My modified technique is aimed at preserving the muscular part of the Intra-Prostatic Urethra in low volume disease. Material & Methods: 98 patients within the age group of 54–67 treated between 2000 and 2011 were analyzed. 23 patients with low volume disease were chosen for Full Functional Length Urethral Preservation (FFLU) while 75 had non-FFLU. Continence rate was assessed at 1 month and 3 months after the catheter removal. The proximal urethral tissue was sent for frozen section. Results: The continence rate at one month after the catheter removal was defined as no pad at all or one protective pad was used 79.9% with FFLU and that with non-FFLU was 68.2%. After 3 months, the continence rate rose to 96.7% and 80.4% respectively. The other factors considered in the study are age, PT stage, prostatectomy Gleason score. The positive surgical margin rate was 1.6% with FFLU while the one with non-FFLU was 2.2% Conclusions: The improved Urinary Continence Rate achieved by doing this technique shows that this simple manoeuvre of Full Functional Length Urethral Preservation (FFLU) in low volume disease should be attempted wherever possible.
Advanced prostate cancer P063 Staging of biochemical recurrent prostate cancer after radical prostatectomy using 68Gallium-labelled ligand of prostate-specific membrane antigen PET/CT and PET/MRI T. Maurer, V. Beck, A.J. Beer, M. Souvatzoglou, K. Holzapfel, H. Kübler, J.E. Gschwend, H-J. Wester, B. Haller, M. Schwaiger, M. Eiber. Klinikum rechts der Isar der Technischen Universität München, Dept. of Urology, Munich, Germany Introduction & Objectives: Staging of recurrent prostate cancer after curative intended radical prostatectomy (RPE) remains challenging especially at low PSA values. Recently, Glu-NH-CO-NH-Lys(Ahx)-[68 Ga(HBED-CC)] as a novel 68 Gallium-labelled ligand of the prostate-specific membrane antigen (68 Ga-HBED-PSMA) has been developed. PSMA shows a selective and marked expression on the cell surface of prostate cancer cells. Thus, the aim of this study was to investigate the detection rate of 68 Ga-HBED-PSMA PET/CT and PET/MRimaging in patients with biochemical recurrence of prostate cancer after RPE. Material & Methods: This retrospective analysis included 332 patients with a median PSA-level of 1.7 ng/ml (range 0.2–63 ng/ml). After injection of 122±17 MBq 68 Ga-HBED-PSMA contrastenhanced PET/CT or fully-diagnostic PET/MR including multiparametric prostate MR was performed in 256 patients and 76 patients, respectively. Images were reviewed by one nuclear medicine physician and one radiologist in consensus. Findings were rated as suspicious or highly suggestive for recurrent prostate cancer. Results: For PET/CT and PET/MR detection rates for PSA-values ≥2 ng/ml, were 96.1% (122/127) and 95.5% (21/22), for PSA-values 1–2 ng/ml 94.4% (67/71) and 81.3% (13/16), for PSA-values 0.5–1 ng/ml 71.4% (25/35) and 75.0% (9/12) and for PSA-value 0.2–0.5 ng/ml 56.5% (13/23) and 50.0% (13/26), respectively. Especially in cases with low PSA-values the diagnostic certainty was substantially higher in PET/MR compared to PET/CT: for PSA-values 0.2–0.5 ng/ml 38.5% vs. 69.2% of positive findings on PET/CT vs. PET/MR were rated as highly suggestive for prostate cancer recurrence. Conclusions: 68 Ga-HBED-PSMA PET-imaging shows higher detection rates for patients with recurrent prostate cancer than reported for other tracers especially at low PSA-values and most likely will replace other tracers like 18 F-FDG or choline derivatives in clinical practice. As salvage therapy is most effective at low PSA-levels, early detection of cancerous foci by 68 Ga-HBED-PSMA PET-imaging might improve oncological results. PET/MR might be advantageous in patients with PSA <1 ng/ml as multiparametric MR provides additional information, thus increasing the diagnostic certainty. P064 To prospectively compare F18-Choline PET/CT and axial skeleton MRI for the detection of bone metastases in patients with biochemically recurrent prostate cancer (PCa) P. Ost 1 , W. Huysse 2 , L. Delrue 2 , K. Decaestecker 3 , G. De Meerleer 1 , F. De Vos 4 , V. Fonteyne 1 , B. Lambert 5 . 1 Universitair Ziekenhuis Gent, Dept. of Radiotherapy, Ghent, Belgium; 2 Universitair Ziekenhuis Gent, Dept. of Radiology, Ghent, Belgium; 3 Universitair Ziekenhuis Gent, Dept. of Urology, Ghent, Belgium; 4 Universiteit Gent, Dept. of Radiopharmacy, Ghent, Belgium; 5 Universitair Ziekenhuis Gent, Dept. of Nuclear Medicine, Ghent, Belgium Introduction & Objectives: To compare F18-Choline PET-CT and axial skeleton MRI (AS-MRI) in detecting bone metastases in hormonenaïve prostate cancer (PCa) patients with a biochemical recurrence following curative treatment. Material & Methods: PCa patients with a biochemical relapse follow-
A B S T R A C T S / E U R O P E A N U R O L O G Y S U P P L E M E N T S 13 (2014) 103—194
with cancer, but which were not specific for urological cancer, were not included in this study. Each of the selected apps was reviewed by three graders to unanimously determine their price, type of developer (individual or company), target audience (health care professional or general population) and type of cancer. Results: We found 139 iOS applications designed for urology, of which 19% were cancer specific, and 128 Android urological applications, 12% of which were cancer specific. All variables were compared between Android and iOS apps using Chi-square goodness-offit test for the numbers of apps and Fisher exact testing (for nominal variables). There was no statistically significant difference between the number of urological cancer apps in both stores (p=0.086). Moreover, Fisher test shows that there was no statistically significant differences between Android and iOS in app price (paid or free, p=0.129), type of developer (p=0.566) and target audience (p=0.507). From a total of 34 urological cancer specific apps, 21% were available in both stores, 56% were exclusively on Apple’s App Store and 24% on Google’s Play Store. The majority were free (56%), developed by companies (65%) and designed for the general population (59%). Most were prostate cancer specific (74%); 9% were for general urological cancers, 9% for testicular, 6% for bladder and 3% for renal cell cancer. There were no apps specific for upper urinary tract, urethral or penile cancer. Conclusions: To our knowledge, this is the first study that completely reviews and compares mobile apps designed for urological cancer. There are some apps available exclusively in a specific platform, which could represent the difference in review policy (all iOS apps have to be approved by Apple; Android apps are mostly unregulated). We can conclude that urological cancer specific apps represent less than a quarter of all urology related apps, with no statistically significant differences between the two most popular mobile platforms. In addition, the total number of available urological cancer specific apps is much lower than that of breast cancer (total = 238, Android = 138, iOS = 100). With the foreseeable growth of the mHealth app market, expected to reach a value of more than USD 26bn in 2017, we look forward to an increase in the quantity and quality of available medical apps. P062 Full functional length urethral sphincter preservation during open radical prostatectomy – will it improve the continence rate? R.K. Shimpi. Uro-Andrology Clinic, Dept. of Urology, Pune, India Introduction & Objectives: The full length of the urethral sphincter is the key for urinary continence after Radical Prostatectomy. As demonstrated by various studies, the Intra-Prostatic Urethra between the apex and verumontanum is an important part of the urethral sphincter complex. My modified technique is aimed at preserving the muscular part of the Intra-Prostatic Urethra in low volume disease. Material & Methods: 98 patients within the age group of 54–67 treated between 2000 and 2011 were analyzed. 23 patients with low volume disease were chosen for Full Functional Length Urethral Preservation (FFLU) while 75 had non-FFLU. Continence rate was assessed at 1 month and 3 months after the catheter removal. The proximal urethral tissue was sent for frozen section. Results: The continence rate at one month after the catheter removal was defined as no pad at all or one protective pad was used 79.9% with FFLU and that with non-FFLU was 68.2%. After 3 months, the continence rate rose to 96.7% and 80.4% respectively. The other factors considered in the study are age, PT stage, prostatectomy Gleason score. The positive surgical margin rate was 1.6% with FFLU while the one with non-FFLU was 2.2% Conclusions: The improved Urinary Continence Rate achieved by doing this technique shows that this simple manoeuvre of Full Functional Length Urethral Preservation (FFLU) in low volume disease should be attempted wherever possible.
Advanced prostate cancer P063 Staging of biochemical recurrent prostate cancer after radical prostatectomy using 68Gallium-labelled ligand of prostate-specific membrane antigen PET/CT and PET/MRI T. Maurer, V. Beck, A.J. Beer, M. Souvatzoglou, K. Holzapfel, H. Kübler, J.E. Gschwend, H-J. Wester, B. Haller, M. Schwaiger, M. Eiber. Klinikum rechts der Isar der Technischen Universität München, Dept. of Urology, Munich, Germany Introduction & Objectives: Staging of recurrent prostate cancer after curative intended radical prostatectomy (RPE) remains challenging especially at low PSA values. Recently, Glu-NH-CO-NH-Lys(Ahx)-[68 Ga(HBED-CC)] as a novel 68 Gallium-labelled ligand of the prostate-specific membrane antigen (68 Ga-HBED-PSMA) has been developed. PSMA shows a selective and marked expression on the cell surface of prostate cancer cells. Thus, the aim of this study was to investigate the detection rate of 68 Ga-HBED-PSMA PET/CT and PET/MRimaging in patients with biochemical recurrence of prostate cancer after RPE. Material & Methods: This retrospective analysis included 332 patients with a median PSA-level of 1.7 ng/ml (range 0.2–63 ng/ml). After injection of 122±17 MBq 68 Ga-HBED-PSMA contrastenhanced PET/CT or fully-diagnostic PET/MR including multiparametric prostate MR was performed in 256 patients and 76 patients, respectively. Images were reviewed by one nuclear medicine physician and one radiologist in consensus. Findings were rated as suspicious or highly suggestive for recurrent prostate cancer. Results: For PET/CT and PET/MR detection rates for PSA-values ≥2 ng/ml, were 96.1% (122/127) and 95.5% (21/22), for PSA-values 1–2 ng/ml 94.4% (67/71) and 81.3% (13/16), for PSA-values 0.5–1 ng/ml 71.4% (25/35) and 75.0% (9/12) and for PSA-value 0.2–0.5 ng/ml 56.5% (13/23) and 50.0% (13/26), respectively. Especially in cases with low PSA-values the diagnostic certainty was substantially higher in PET/MR compared to PET/CT: for PSA-values 0.2–0.5 ng/ml 38.5% vs. 69.2% of positive findings on PET/CT vs. PET/MR were rated as highly suggestive for prostate cancer recurrence. Conclusions: 68 Ga-HBED-PSMA PET-imaging shows higher detection rates for patients with recurrent prostate cancer than reported for other tracers especially at low PSA-values and most likely will replace other tracers like 18 F-FDG or choline derivatives in clinical practice. As salvage therapy is most effective at low PSA-levels, early detection of cancerous foci by 68 Ga-HBED-PSMA PET-imaging might improve oncological results. PET/MR might be advantageous in patients with PSA <1 ng/ml as multiparametric MR provides additional information, thus increasing the diagnostic certainty. P064 To prospectively compare F18-Choline PET/CT and axial skeleton MRI for the detection of bone metastases in patients with biochemically recurrent prostate cancer (PCa) P. Ost 1 , W. Huysse 2 , L. Delrue 2 , K. Decaestecker 3 , G. De Meerleer 1 , F. De Vos 4 , V. Fonteyne 1 , B. Lambert 5 . 1 Universitair Ziekenhuis Gent, Dept. of Radiotherapy, Ghent, Belgium; 2 Universitair Ziekenhuis Gent, Dept. of Radiology, Ghent, Belgium; 3 Universitair Ziekenhuis Gent, Dept. of Urology, Ghent, Belgium; 4 Universiteit Gent, Dept. of Radiopharmacy, Ghent, Belgium; 5 Universitair Ziekenhuis Gent, Dept. of Nuclear Medicine, Ghent, Belgium Introduction & Objectives: To compare F18-Choline PET-CT and axial skeleton MRI (AS-MRI) in detecting bone metastases in hormonenaïve prostate cancer (PCa) patients with a biochemical recurrence following curative treatment. Material & Methods: PCa patients with a biochemical relapse follow-